Wednesday, November 11, 2020 12:32:01 PM
November 10, 2020 08:35 ET | Source: Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., Equillium’s chief medical officer, will present at two upcoming investor conferences in November 2020.
Event:
Date:
Time:
Location: Stifel 2020 Virtual Healthcare Conference
Wednesday, November 18, 2020
3:20 PM Eastern Time | 12:20 PM Pacific Time
Virtual Webcast
Event:
Date:
Time:
Location: Jefferies Virtual London Healthcare Conference
Thursday, November 19, 2020
6:10 PM GMT | 1:10 PM Eastern Time | 10:10 AM PM Pacific Time
Virtual Webcast
Live webcasts of both presentations will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.
About Itolizumab
Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is currently being evaluated in multiple clinical trials in patients with severe diseases, including aGVHD, lupus nephritis, uncontrolled asthma, and will soon be evaluated in a clinical trial of patients with COVID-19. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Itolizumab is marketed in India under the trade name “ALZUMAb-L” for the treatment of chronic plaque psoriasis and has received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including COVID-19, aGVHD, lupus nephritis and uncontrolled asthma.
For more information, visit www.equilliumbio.com.
Investor Contact
Christine Zedelmayer, Chief Operating Officer
+1-858-412-5302
ir@equilliumbio.com
Media Contact
Katherine Carlyle Smith
Senior Account Associate
Canale Communications
+1-805-907-2497
katherine.smith@canalecomm.com
"Then there was a woman, a lion of a woman."
Recent EQ News
- Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists • Business Wire • 05/07/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 12:00:00 PM
- Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis • Business Wire • 04/01/2024 12:00:00 PM
- Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights • Business Wire • 03/25/2024 08:01:00 PM
- Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference • Business Wire • 03/22/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:35:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:01:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 10:12:11 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/23/2024 10:09:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 11:08:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:17:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:14:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:12:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 01:05:52 PM
- Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease • Business Wire • 12/21/2023 01:00:00 PM
- EQ Bank Card launches in Québec as Carte Banque EQ • PR Newswire (Canada) • 11/20/2023 04:23:00 PM
- EQ Bank Card launches in Québec as Carte Banque EQ • PR Newswire (US) • 11/20/2023 04:23:00 PM
- Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology • Business Wire • 11/13/2023 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:10:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:05:10 PM
- Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates • Business Wire • 11/08/2023 09:01:00 PM
- Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology • Business Wire • 11/06/2023 01:00:00 PM
- Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology • Business Wire • 10/19/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 12:05:52 PM
- Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium • Business Wire • 10/16/2023 12:00:00 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM